“DDP’s an event that has for the past two decades been an important meeting place for drug delivery leaders. With the increased use of biologic and biosimilar formulations to treat chronic indications, SHL’s safe and reliable self-injection offerings meet the industry’s demand for efficient drug delivery devices that are designed to improve treatment outcomes,” said Jamie Gould, Manager of Business Development at SHL Pharma.
During the event, SHL will introduce the groundbreaking Maggie®, a two-step cartridge-based auto injector for high-volume injections built with SHL’s market-proven Needle Isolation Technology (NIT®). Also on display is Bertha®, a versatile auto injector that can accommodate a wide range of fill volumes and viscosities.
SHL will also present its Molly® 2.25 auto injector. Designed with the same robust features as the classic Molly® family of preconfigured devices, this high-volume variation is equally safe and intuitive, and offers the same flexibility and short development timelines for faster commercialization.
To find out more about SHL’s latest innovations and comprehensive solutions for device commercialization, visit Booth 301 at the PGA National Resort & Spa in Palm Beach Gardens, Florida.